CYP3A4 Metabolism Before and After Surgery Induced Weight Loss Using Midazolam as Model Drug

CYP3A4 Metabolism Before and After Surgery Induced Weight Loss in Morbidly Obese Patients Using Midazolam as a Model Drug

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01519726

Acronym

MEMO

Enrollment

Registered

2012-01-27

Start date

2011-12-31

Completion date

2013-12-31

Last updated

2019-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Morbid Obesity

Brief summary

Before and during bariatric surgery patients are given oral and i.v. midazolam, respectively and blood samples are drawn to establish midazolam time-concentration profiles. After 0.5-2 years, and substantial weight loss, oral and i.v. midazolam are administered once more and blood samples are taken again.

Interventions

DRUGMidazolam

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* BMI\>40 * undergoing bariatric surgery

Exclusion criteria

* use of drug inducing or inhibiting CYP3A4 activity * pregnancy, breastfeeding * renl insufficiency

Design outcomes

Primary

Measure	Time frame
Difference in midazolam clearance in morbidly obese patients before and 0.5-2 years after surgery	0.5-2 years

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026